Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 06, 2020 07:30 ET | Source: Albireo Pharma, Inc.

Albireo Reports Q2 2020 Financial Results and Provides Business Update

— Completed last patient visits in Phase 3 PFIC and Phase 2 NASH Trials —— Enrolled first biliary atresia patients in second odevixibat pivotal study —— Completed two financing transactions to secure...
July 30, 2020 16:01 ET | Source: Albireo Pharma, Inc.

Albireo to Present at the William Blair Biotech Focus Conference 2020

BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron...
July 30, 2020 08:00 ET | Source: Albireo Pharma, Inc.

Albireo to Report Q2 2020 Financial Results on August 6

— Conference call and webcast to be held at 10:00 a.m. ET — BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company...
July 20, 2020 08:00 ET | Source: Albireo Pharma, Inc.

Albireo Launches Expanded Access Program for Odevixibat for Patients in the U.S., Canada, Australia and Europe

BOSTON, July 20, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the...
July 14, 2020 07:30 ET | Source: Albireo Pharma, Inc.

Albireo Enrolls First Patient in Phase 3 Clinical Trial of Odevixibat in Biliary Atresia

— BOLD is first-ever pivotal trial for biliary atresia — — Trial expands odevixibat’s development program into second rare cholestatic liver disease — BOSTON, July 14, 2020 (GLOBE NEWSWIRE) --...
June 10, 2020 08:00 ET | Source: Albireo Pharma, Inc.

Albireo to Host Key Opinion Leader Call on Clinical Outcome Assessments

BOSTON, June 10, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that it...
June 09, 2020 07:30 ET | Source: Albireo Pharma, Inc.

Albireo Announces Two Financing Transactions to Extend Cash Runway Into the Beginning of 2022

— Restructured HealthCare Royalty Partners elobixibat royalty monetization agreement nets additional $15M in non-dilutive capital — — Initial draw down of $10M on debt facility of up to $80M with...
May 26, 2020 08:00 ET | Source: Albireo Pharma, Inc.

Albireo to Present at 2020 Jefferies Virtual Healthcare Conference

BOSTON, May 26, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron...
May 07, 2020 07:30 ET | Source: Albireo Pharma, Inc.

Albireo Reports Q1 2020 Financial Results and Provides Business Update

— Commercial preparations advancing, with topline PEDFIC 1 results expected mid-2020 —— First sites initiated for second pivotal trial in biliary atresia —— Management to host conference call and...
April 30, 2020 09:47 ET | Source: Albireo Pharma, Inc.

Albireo to Report First Quarter 2020 Financial Results on May 7

BOSTON, April 30, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that...